259 related articles for article (PubMed ID: 31295061)
1. Antimicrobial Susceptibility and Molecular Epidemiology of
Lin MF; Liou ML; Kuo CH; Lin YY; Chen JY; Kuo HY
Microb Drug Resist; 2019 Nov; 25(9):1338-1346. PubMed ID: 31295061
[TBL] [Abstract][Full Text] [Related]
2. Antimicrobial susceptibilities of Proteus mirabilis: a longitudinal nationwide study from the Taiwan surveillance of antimicrobial resistance (TSAR) program.
Wang JT; Chen PC; Chang SC; Shiau YR; Wang HY; Lai JF; Huang IW; Tan MC; Lauderdale TL;
BMC Infect Dis; 2014 Sep; 14():486. PubMed ID: 25192738
[TBL] [Abstract][Full Text] [Related]
3. Molecular drivers of emerging multidrug resistance in Proteus mirabilis clinical isolates from Algeria.
Boudjemaa H; Allem R; Fonkou MDM; Zouagui S; Khennouchi NCEH; Kerkoud M
J Glob Antimicrob Resist; 2019 Sep; 18():249-256. PubMed ID: 30797091
[TBL] [Abstract][Full Text] [Related]
4. Rapidly spreading CTX-M-type beta-lactamase-producing Proteus mirabilis in Japan.
Kanayama A; Iyoda T; Matsuzaki K; Saika T; Ikeda F; Ishii Y; Yamaguchi K; Kobayashi I
Int J Antimicrob Agents; 2010 Oct; 36(4):340-2. PubMed ID: 20609568
[TBL] [Abstract][Full Text] [Related]
5. Properties of multidrug-resistant, ESBL-producing Proteus mirabilis isolates and possible role of beta-lactam/beta-lactamase inhibitor combinations.
Luzzaro F; Perilli M; Amicosante G; Lombardi G; Belloni R; Zollo A; Bianchi C; Toniolo A
Int J Antimicrob Agents; 2001 Feb; 17(2):131-5. PubMed ID: 11165117
[TBL] [Abstract][Full Text] [Related]
6. [Plasmid-mediated AMPc producing Proteus mirabilis in the Health Care Area of Santiago de Compostela: molecular and epidemiological analysis by rep-PCR and MALDI-TOF].
Treviño M; Navarro D; Barbeito G; Areses P; García-Riestra C; Regueiro BJ
Rev Esp Quimioter; 2012 Jun; 25(2):122-8. PubMed ID: 22707100
[TBL] [Abstract][Full Text] [Related]
7. Nosocomial outbreak by Proteus mirabilis producing extended-spectrum beta-lactamase VEB-1 in a Korean university hospital.
Kim JY; Park YJ; Kim SI; Kang MW; Lee SO; Lee KY
J Antimicrob Chemother; 2004 Dec; 54(6):1144-7. PubMed ID: 15546971
[TBL] [Abstract][Full Text] [Related]
8. Dissemination of Proteus mirabilis isolates harboring CTX-M-14 and CTX-M-3 beta-lactamases at 2 hospitals in Taiwan.
Wu LT; Wu HJ; Chung JG; Chuang YC; Cheng KC; Yu WL
Diagn Microbiol Infect Dis; 2006 Feb; 54(2):89-94. PubMed ID: 16406185
[TBL] [Abstract][Full Text] [Related]
9. Molecular epidemiology and antimicrobial susceptibility of AmpC- and/or extended-spectrum (ESBL) ß-lactamaseproducing Proteus spp. clinical isolates in Zenica-Doboj Canton, Bosnia and Herzegovina.
Uzunović S; Ibrahimagić A; Hodžić D; Bedenić B
Med Glas (Zenica); 2016 Aug; 13(2):103-12. PubMed ID: 27313108
[TBL] [Abstract][Full Text] [Related]
10. Emergence of multidrug-resistant Proteus mirabilis in a long-term care facility in Croatia.
Bedenić B; Firis N; Elveđi-Gašparović V; Krilanović M; Matanović K; Štimac I; Luxner J; Vraneš J; Meštrović T; Zarfel G; Grisold A
Wien Klin Wochenschr; 2016 Jun; 128(11-12):404-13. PubMed ID: 27220339
[TBL] [Abstract][Full Text] [Related]
11. Regional outbreak of CTX-M-2 β-lactamase-producing Proteus mirabilis in Japan.
Nakano R; Nakano A; Abe M; Inoue M; Okamoto R
J Med Microbiol; 2012 Dec; 61(Pt 12):1727-1735. PubMed ID: 22935848
[TBL] [Abstract][Full Text] [Related]
12. Regional Spread of CTX-M-2-Producing Proteus mirabilis with the Identical Genetic Structure in Japan.
Kato K; Matsumura Y; Yamamoto M; Nagao M; Takakura S; Ichiyama S
Microb Drug Resist; 2017 Jul; 23(5):590-595. PubMed ID: 27834610
[TBL] [Abstract][Full Text] [Related]
13. Antimicrobial susceptibility of clinical Enterobacteriaceae isolates at the emergency department in a regional hospital: A threat of extended spectrum beta-lactamase-producers among nursing home residents.
Liu HC; Hung YP; Lin HJ; Liu HC; Lee JC; Wu YH; Li CW; Li MC; Ko WC
J Microbiol Immunol Infect; 2016 Aug; 49(4):584-90. PubMed ID: 26692184
[TBL] [Abstract][Full Text] [Related]
14. Molecular epidemiology of CTX-M-type extended-spectrum β-lactamase-producing Proteus mirabilis isolates in Taiwan.
Huang CW; Chien JH; Peng RY; Tsai DJ; Li MH; Lee HM; Lin CF; Lee MC; Liao CT
Int J Antimicrob Agents; 2015 Jan; 45(1):84-5. PubMed ID: 25446905
[No Abstract] [Full Text] [Related]
15. Spread of multidrug-resistant Proteus mirabilis isolates producing an AmpC-type beta-lactamase: epidemiology and clinical management.
Luzzaro F; Brigante G; D'Andrea MM; Pini B; Giani T; Mantengoli E; Rossolini GM; Toniolo A
Int J Antimicrob Agents; 2009 Apr; 33(4):328-33. PubMed ID: 19095415
[TBL] [Abstract][Full Text] [Related]
16. Molecular Characterization of β-Lactam Resistance and Antimicrobial Susceptibility to Possible Therapeutic Options of AmpC-Producing Multidrug-Resistant
Rubic Z; Soprek S; Jelic M; Novak A; Goic-Barisic I; Radic M; Tambic-Andrasevic A; Tonkic M
Microb Drug Resist; 2021 Feb; 27(2):162-169. PubMed ID: 32429775
[TBL] [Abstract][Full Text] [Related]
17. In vitro activity of flomoxef and comparators against Escherichia coli, Klebsiella pneumoniae and Proteus mirabilis producing extended-spectrum β-lactamases in China.
Yang Q; Zhang H; Cheng J; Xu Z; Xu Y; Cao B; Kong H; Ni Y; Yu Y; Sun Z; Hu B; Huang W; Wang Y; Wu A; Feng X; Liao K; Shen D; Hu Z; Chu Y; Lu J; Su J; Gui B; Duan Q; Zhang S; Shao H
Int J Antimicrob Agents; 2015 May; 45(5):485-90. PubMed ID: 25600890
[TBL] [Abstract][Full Text] [Related]
18. Distribution and antimicrobial susceptibility profile of extended-spectrum β-lactamase-producing Proteus mirabilis strains recently isolated in Japan.
Kanayama A; Kobayashi I; Shibuya K
Int J Antimicrob Agents; 2015 Feb; 45(2):113-8. PubMed ID: 25182712
[TBL] [Abstract][Full Text] [Related]
19. Molecular diversity of Proteus mirabilis isolates producing extended-spectrum beta-lactamases in a French university hospital.
Biendo M; Thomas D; Laurans G; Hamdad-Daoudi F; Canarelli B; Rousseau F; Castelain S; Eb F
Clin Microbiol Infect; 2005 May; 11(5):395-401. PubMed ID: 15819867
[TBL] [Abstract][Full Text] [Related]
20. Relationship between the distribution of cefepime minimum inhibitory concentrations and detection of extended-spectrum β-lactamase production among clinically important Enterobacteriaceae isolates obtained from patients in intensive care units in Taiwan: results from the Surveillance of Multicenter Antimicrobial Resistance in Taiwan (SMART) in 2007.
Jean SS; Lee WS; Bai KJ; Lam C; Hsu CW; Yu KW; Liao CH; Chang FY; Ko WC; Wu JJ; Chen YH; Chen YS; Liu JW; Lu MC; Liu CY; Chen RJ; Hsueh PR
J Microbiol Immunol Infect; 2015 Feb; 48(1):85-91. PubMed ID: 23973410
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
